AstraZeneca PLC AZ out-licensing deal with Allergan completed (3960P)
17 November 2016 - 6:00PM
UK Regulatory
TIDMAZN
RNS Number : 3960P
AstraZeneca PLC
17 November 2016
17 November 2016 07:00
MEDIMMUNE COMPLETES OUT-LICENSING
AGREEMENT WITH ALLERGAN FOR MEDI2070
AstraZeneca today announced the completion of the licensing
agreement between MedImmune, its global biologics research and
development arm, and Allergan plc, for the global rights to
MEDI2070.
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase
IIb clinical trial for moderate-to-severe Crohn's disease and ready
for Phase II for ulcerative colitis, diseases that sit outside
AstraZeneca's three main therapy areas.
AstraZeneca will not retain a significant ongoing interest in
MEDI2070. Therefore, income from the transaction will be reported
as Other Operating Income in the Company's financial statements,
including the upfront payment, which will be booked in the fourth
quarter of 2016, and development and sales-related milestones and
tiered royalties on potential sales of the medicine.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three main therapy areas - Oncology, Cardiovascular & Metabolic
Diseases and Respiratory. The Company also is selectively active in
the areas of autoimmunity, neuroscience and infection. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit www.astrazeneca.com and follow us on Twitter
@AstraZeneca.
Media Enquiries
Neil Burrows UK/Global +44 203 749 5637
Vanessa Rhodes UK/Global +44 203 749 5736
Karen Birmingham UK/Global +44 203 749 5634
Rob Skelding UK/Global +44 203 749 5821
Jacob Lund Sweden +46 8 553 260 20
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Craig Marks Finance, Fixed Income, M&A +44 7881 615 764
Henry Wheeler Oncology +44 203 749 5797
Mitchell Chan Oncology +1 240 477 3771
Lindsey Trickett Cardiovascular & Metabolic Diseases +1 240 543 7970
Nick Stone Respiratory +44 203 749 5716
Christer Gruvris Autoimmunity, neuroscience & infection +44 203 749 5711
US toll free +1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGRBFBPTMBMBBPF
(END) Dow Jones Newswires
November 17, 2016 02:00 ET (07:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025
